UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2024 (
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01. | Completion of Acquisition or Disposition of Assets. |
On November 1, 2024, Tredegar Corporation (“Tredegar”) completed the previously announced sale of 100% of the issued and outstanding equity interests of Terphane LLC (“Terphane”) and Terphane Limitada (“Limitada” and together with Terphane, the “Companies”), which together represent the subsidiaries of the Company that had operated Tredegar’s flexible packaging films business headquartered in Brazil (the “Terphane Divestiture”) to Oben US, LLC (f/k/a Packfilm US, LLC) (“Oben US”) and Film Trading Importaçãcao e Representaçãcao Ltda. (“Film Trading” and together with Oben US, “Buyers”) for an aggregate purchase price of $116 million pursuant to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated as of September 1, 2023, by and among Buyers, the Companies, Tredegar Film Products (Latin America), Inc. (“LatAm”), Terphane Acquisition Corp. II (“Tac II”), TAC Holdings, LLC (“TAC”), Tredegar Investments LLC (“Investments” and together with LatAm, Tac II and TAC, “Sellers”), Tredegar and Oben Holding Group S.A.C (“Oben Parent”).
The Terphane Divestiture is more fully described in Item 1.01 of Tredegar’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 5, 2023, which description is incorporated herein by reference.
Item 7.01. | Regulation FD Disclosure. |
On November 1, 2024, Tredegar issued a press release announcing the completion of the Terphane Divestiture. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated in this Item 7.01 by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. | Other Events. |
Tredegar completed the Terphane Divestiture on November 1, 2024 (and, for accounting purposes, on October 31, 2024).
To facilitate an end-of-month closing for accounting purposes, on October 31, 2024, Sellers, Buyers, the Companies, Oben Parent and Tredegar entered into that certain First Amendment to Purchase and Sale Agreement, dated October 31, 2024 (the “First Amendment”), which amends the Purchase and Sale Agreement to, among other items, provide for a legal closing on November 1, 2024 with an accounting effective time as of 11:59 p.m. Eastern Time on October 31, 2024. Additionally, on November 1, 2024, Tredegar, the Companies and Oben Parent entered into a transition services agreement pursuant to which Tredegar will provide certain payroll, finance, tax and information technology services to support the Companies and Buyers in the ongoing operations of the flexible packaging films business.
The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the First Amendment, a copy of which is attached hereto as Exhibit 2.2, and is incorporated herein by reference.
Item 9.01. | Financial Statement and Exhibits. |
(b) Pro forma financial information.
Unaudited pro forma condensed consolidated financial information of Tredegar reflecting the Terphane Divestiture, including the unaudited pro forma condensed consolidated balance sheet as of June 30, 2024; the unaudited pro forma condensed consolidated statements of operations for the six months ended June 30, 2024 and for each of the years ended December 31, 2023, 2022 and 2021; and notes thereto, is attached hereto as Exhibit 99.2 and incorporated herein by reference.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TREDEGAR CORPORATION | |||||
|
|
(Registrant) | ||||
Date: November 6, 2024 | By: | /s/ Kevin C. Donnelly | ||||
|
|
Kevin C. Donnelly | ||||
|
|
Vice President, General Counsel and Corporate Secretary |
Exhibit 2.2
Execution Version
FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT
This First Amendment to Purchase and Sale Agreement (this Amendment) is entered into on October 31, 2024 by and among Oben US, LLC (f/k/a Packfilm US, LLC), a Delaware limited liability company (Packfilm), Film Trading Importação e Representação Ltda., a Brazilian limited liability company (Film Trading and together with Packfilm, Buyers and each, a Buyer), Terphane LLC, a Delaware limited liability company (Terphane LLC), Terphane Limitada, a Brazilian limited liability company (Limitada and together with Terphane LLC, the Companies and each, a Company), Tredegar Film Products (Latin America), Inc., a Virginia corporation (LatAm), Terphane Acquisition Corp. II, a Cayman Islands exempted company (Tac II), TAC Holdings, LLC, a Virginia limited liability company (TAC), Tredegar Investments LLC, a Virginia limited liability company (Investments and together with LatAm, Tac II and TAC, Sellers and each, a Seller), and Tredegar Corporation, a Virginia corporation, in its capacity as representative of the Sellers (in such capacity, Sellers Representative) and for the purposes of guaranteeing Sellers payment and performance obligations under the Purchase Agreement (defined below) (in such capacity, Sellers Parent), and Oben Holding Group S.A.C., a Peruvian company in its capacity as representative of the Buyers (in such capacity, Buyers Representative) and for the purposes of guaranteeing Buyers payment and performance obligations under the Purchase Agreement (in such capacity, Buyers Parent), and amends that certain Purchase and Sale Agreement, dated September 1, 2023 (the Purchase Agreement), by and among Buyers, Sellers, the Companies, and, in the capacities described above, Sellers Representative, Sellers Parent, Buyers Representative and Buyers Parent. Capitalized terms used and not otherwise defined herein have the meanings ascribed to such terms in this Amendment or in the Purchase Agreement.
RECITAL
WHEREAS, in furtherance of the closing of the transactions contemplated by the Purchase Agreement, the parties hereto desire to enter into this Amendment for the purposes, inter alia, of allowing closing for all legal purposes to occur at November 1, 2024, with October 31, 2024 being the Accounting Effective Date, permitting Buyers and their Affiliates to retain certain Indebtedness obligations of the Companies and their Affiliates and including certain additional closing deliverables related thereto.
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
1.1 Definitions.
(a) Section 1.1 of the Purchase Agreement is amended to add the following defined terms:
2019 Intercompany Credit Facility has the meaning set forth in Schedule 5.11(a).
Accounting Effective Date means October 31, 2024.
Intercompany Debt means the aggregate amount that LatAm owes to Limitada at the Effective Time for the borrowing LatAm made pursuant to the terms and conditions of the Fourth Amendment, dated October 26, 2023, to the 2019 Intercompany Credit Facility in the principal amount of $20,000,000, which principal amount accrues interest at an annual rate equal to SOFR plus 5.99% per annum, plus an additional 4.65% to cover the Taxes associated with the Social Contribution on Billing (COFINS) and the Contribution to the Social Integration Program (PIS) that Limitada will be required to pay under applicable Brazilian Law to the applicable Brazilian Tax Authorities when the Intercompany Debt is repaid.
IOF Tax means the Tax on Financial Operations (IOF) due and payable to the applicable Brazilian Tax Authority as a result of Film Tradings assumption of the Intercompany Debt pursuant to the Debt Assumption Agreement.
Santander Agreements means the Santander Loan, the Santander LOC and the Santander Security Contracts.
Santander Loan means that certain Cédula de Crédito Bancário (Bank Credit Note) entered into on October 26, 2023 by and between Limitada, as borrower, and Santander Luxembourg, as lender, pursuant to which Limitada borrowed the principal amount of $20,000,000 from Santander Luxembourg, which principal amount accrues interest at a rate equal to SOFR plus 5.63% per annum (calculated to include the amount of the withholding Tax that Limitada is required to remit under applicable Brazilian Law to the applicable Brazilian Tax Authorities when interest on the Santander Loan is paid to Santander Luxembourg).
Santander LOC means that certain standby letter of credit issued by Banco Santander (Brasil) S.A. guaranteeing Limitadas obligation to repay the Santander Loan.
Santander Luxembourg means Banco Santander (Brasil) S.A., Luxembourg Branch.
Santander Security Contracts means that certain Contract of Fiduciary Assignment of Receivables (Instrumento de Cessão Fiduciária de Direitos Creditórios), dated October 26, 2023, and that certain Contract of Fiduciary Assignment of Sale Bills and Cheques (Instrumento de Cessão Fiduciária de Duplicatas e/ou Cheques) dated October 26, 2023, each entered into by and between Santander Luxembourg and Limitada.
SOFR means a rate equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
2
(b) The following defined terms in Section 1.1 of the Purchase Agreement are amended and restated as set forth below:
Effective Time means 11:59 p.m., Eastern Time, on the Accounting Effective Date.
Indebtedness means (without duplication of any of the clauses below or any amounts specifically taken into account in the Net Working Capital Adjustment or in the calculation of Transaction Expenses): (a) any indebtedness or other obligation of either Company for borrowed money, whether current, short-term or long-term and whether secured or unsecured, excluding trade payables incurred in the ordinary course of business; (b) any indebtedness of either Company evidenced by any note, bond, debenture or other security or similar instrument; (c) any net liabilities of either Company with respect to interest rate or currency swaps, collars, caps and similar hedging obligations, except foreign currency derivative assets or liabilities classified as Current Assets or Current Liabilities; (d) any liabilities of either Company for the deferred purchase price of property or other assets (including any earn-out or similar payments); (e) any liability of either Company in respect of a finance lease as reflected on the Latest Balance Sheet in accordance with GAAP, including Accounting Standards Codification 842 and related accounting rules and regulations, as such may be amended or re-codified from time to time; (f) any indebtedness (including the types specified in subsections (a) through (e) of this definition) that either Company guarantees or with respect to which either Company otherwise assures a creditor against loss (which, for the avoidance of doubt, does not include contingent reimbursement obligations in respect of letters of credit or surety bonds issued on behalf of either Company with respect to any of its purchases of supplies or equipment in the ordinary course of business); (g) any Taxes (excluding deferred Taxes and net of any applicable deferred Tax assets) due and payable (an increase to Indebtedness) or recoverable (a decrease to Indebtedness) by either Company through and including the Accounting Effective Date but excluding any Tax liabilities of or with respect to either Company (i) that are payable by, or the responsibility of, Sellers pursuant to Section 2.4, Article XI and any other applicable provision of this Agreement, (ii) that are or were included in a consolidated Tax Return with Sellers Parent, or (iii) that are, were, or will be required to be settled directly by Sellers Parent or any of its Affiliates (other than either Company) with the applicable Tax Authority; and (h) any accrued interest, premiums, penalties (including prepayment penalties) and other obligations relating to the foregoing.
Post-Closing Tax Period means, with respect to each Company, any taxable period (or portion thereof) beginning after the Accounting Effective Date.
Pre-Closing Tax Period means, with respect to each Company, any taxable period (or portion of a Straddle Period) ending on or before the Accounting Effective Date.
3
Transaction Expenses means the following fees, costs and expenses incurred or subject to reimbursement by either Company, Sellers Parent or any of the Sellers (without duplication), in each case in connection with the transactions contemplated hereby and incurred and not paid prior to the Closing: (a) any brokerage fees, costs and expenses, commissions, finders fees, costs and expenses or financial advisory fees, costs and expenses; (b) any fees, costs and expenses of counsel, accountants or other advisors or service providers; (c) all costs and expenses related to the R&W Policy, including the total premium, underwriting costs, brokerage commissions, Taxes in connection with binding the R&W Policy, and other fees and expenses of such policy, up to a maximum amount of $650,000; (d) any fees, costs and expenses incurred by, or payment obligations of, either Company and related to any transaction bonus (which, for the avoidance of doubt, include any payments under the Equity Awards and the Incentive Agreements that are due upon Closing) discretionary bonus, success fee, equity award, change-of-control payment, phantom equity payout, stay-put or other compensatory payment obligations to any employee of either Company or Sellers Parent or any of their Affiliates as a result of the execution of this Agreement or in connection with the transactions contemplated by this Agreement; provided, however, that, for the avoidance of doubt, this clause (d) will not apply to any such payment obligations that may be incurred by either Company or Sellers Parent or any of their Affiliates as a result of the termination of an employees employment after the Closing; (e) 50% of the fees and expenses to obtain the Tail Policy; (f) 50% of the fees and expenses of the Escrow Agent and (g) the IOF Tax; provided, however, that Transaction Expenses will not include any obligations of Sellers Parent under the Equity Awards and Incentive Agreements that become due after the Closing, which obligations will not be included in the calculation of Estimated Purchase Price or Final Purchase Price.
1.2 Section 1.2 of the Purchase Agreement. The table set forth under Section 1.2 of the Purchase Agreement is amended to add the following defined terms:
Term |
Section | |
Converted Escrow Amount | 2.2(c) | |
Debt Assumption Agreement | 8.4(m) | |
TSA | 8.4(l) |
1.3 Sections 2.2(b) and 2.2(c) of the Purchase Agreement. Sections 2.2(b) and 2.2(c) of the Purchase Agreement are amended and restated in their entirety as set forth below:
(b) Pre-Closing Statement and Transaction Expenses. Not fewer than two Business Days prior to the Closing Date, (i) Sellers Representative shall deliver to Buyers Representative a statement (the Pre-Closing Statement) setting forth Sellers Representatives good faith estimates of (A) Cash and Cash Equivalents, (B) Closing Indebtedness, (C) Transaction Expenses, (D) Net Working Capital Adjustment, and, based on the foregoing, (E) the Adjustment Amount, in each case determined in accordance with the Accounting Principles (clause (E) being the Estimated Adjustment Amount), (F) the Brazilian
4
Withholding Tax Amount, calculated and to be paid by Film Trading to the Brazilian Tax Authority in accordance with Section 11.8(i), due on the amount obtained by subtracting the Escrow Amount from the Estimated Purchase Price (the Closing Brazilian Withholding Tax Amount), which Closing Brazilian Withholding Tax Amount includes, for the avoidance of doubt, the withholding tax due on the portion of the Estimated Purchase Price that Film Trading is paying to purchase the Quotas as a result of its assumption of the Intercompany Debt, and (G) the Estimated Purchase Price, together with all calculations of the items referred in clauses (A), (B), (C), (D), (E), (F) and (G) of this Section 2.2(b) and all supporting documentation for such estimates and any additional information reasonably requested by Buyers Representative, and (ii) Sellers Representative shall deliver to Buyers Representative final invoices and wire instructions with respect to all Transaction Expenses, which will be paid at the Closing (the Closing Transaction Expenses).
(c) Escrow Amount. Approximately four Business Days prior to the Closing Date, Film Trading will (i) enter a foreign exchange contract with a financial institution pursuant to which the Escrow Amount will be converted into an amount in Reais equal to the Escrow Amount (the Converted Escrow Amount), and (ii) notify Sellers Representative of the Converted Escrow Amount. Approximately two Business Days prior to the Closing Date, Film Trading, Sellers Representative and the Escrow Agent will enter into the Escrow Agreement, and on the Closing Date, Buyers shall deposit the Converted Escrow Amount, by wire transfer of immediately available funds into the Escrow Accounts as designated on the Pre-Closing Statement and in the Escrow Agreement. The Escrow Amount will be disbursed from the Escrow Accounts in accordance with the terms of Sections 2.3(d), 11.1, 11.3 and 11.5, as applicable, and the Escrow Agreement. For the avoidance of doubt, (x) the Escrow Amount and the Converted Escrow Amount shall be included, as applicable, in the Pre-Closing Statement and the Closing Statement regardless of the differences that may exist if the applicable exchange rate for the conversion of USD to Reais on the Accounting Effective Date had been applied, and (y) as applicable, other amounts will be converted from USD to Reais using an estimated rate for the Pre-Closing Statement or the applicable exchange rate on the Accounting Effective Date for the Closing Statement.
1.4 Section 2.4 of the Purchase Agreement. Section 2.4 of the Purchase Agreement is amended and restated in its entirety as set forth below:
2.4 Tax Withholding Generally. Notwithstanding anything in this Agreement to the contrary, and although no tax withholding is currently anticipated other than the Brazilian Withholding Tax Amounts, which will be calculated, withheld and paid by Film Trading in accordance with Section 11.8(i), Buyers shall be entitled to deduct and withhold from amounts payable by Buyers to Sellers under this Agreement such amounts as they are required to deduct and withhold under applicable Law (such amounts, the Withholding Tax Amount), and the Parties will agree upon the Withholding Tax Amount prior to Closing; provided, however, that Buyers shall use commercially reasonable efforts after the date hereof to
5
cooperate with Sellers to mitigate or eliminate the need to deduct and withhold such amounts provided Buyers consider, at its sole discretion, that any such mitigation or elimination is in full compliance with applicable Law; provided, further, that in no event will Buyers deduct and withhold from amounts payable by Buyers to Sellers under this Agreement a total amount in excess of the aggregate amount of the Brazilian Withholding Tax Amounts unless Sellers Representative agrees to such excess Withholding Tax Amount in writing prior to Closing. Deducted and withheld amounts shall be treated for all purposes of this Agreement and the other Transaction Documents as having been paid by Buyers to Sellers. Within 15 Business Days following payment thereof, as provided for in Section 11.8(i), Buyers Representative shall provide Sellers Representative with proof of the payment of the deducted and withheld amount, including providing to Sellers Representative copies of any relevant receipts received or obtainable from a Tax Authority by Buyers or an Affiliate, and, when requested, assist with any refund claims with respect to the deduction and withholding provided (i) Buyers consider that any such assistance is in full compliance with applicable Law and (ii) all the costs and expenses related to such refund claims will be assumed and paid by Sellers Representative. For the avoidance of doubt, a request for a refund of an overpayment of a Withholding Tax Amount based on an increase or decrease to the amount withheld on pursuant to the application of the provisions of Section 2.2, 2.3 or 11.2 shall be considered in full compliance with applicable Law. Notwithstanding any other provision of this Agreement and the other Transaction Documents, Buyers shall fully indemnify Sellers against claims relating to deductions and withholding amounts collected by Buyer under this Section 2.4 that Buyers did not properly remit, or did not cause to be properly remitted, to a Tax Authority within the legal term provided by the applicable Laws, whereas Sellers Representative shall fully indemnify Buyers Representative against claims by any Tax Authority that the deduction and withholding amounts were less than the amounts actually due under applicable Law and Sellers Representative shall be fully responsible for any difference assessed or claimed by any Tax Authority.
1.5 Section 3.1 of the Purchase Agreement. Section 3.1 of the Purchase Agreement is amended and restated in its entirety as set forth below:
3.1 Closing; Closing Date. The closing of the sale and purchase of the Purchased Equity contemplated by this Agreement (the Closing) shall take place remotely via electronic exchange of documents and signatures at approximately 10:00 a.m. Eastern Time on November 1, 2024 so long as all of the conditions to the Closing set forth in Article VIII and Article IX (other than those conditions which, by their terms, are to be satisfied or waived at the Closing, but subject to the satisfaction or waiver of those conditions on the Closing Date) shall have been satisfied or waived by the Party entitled to waive the same, or at such other date that Sellers Representative and Buyers Representative may agree in writing (such date when the Closing occurs is referred to as the Closing Date).
6
1.6 Section 3.2(b) of the Purchase Agreement: Section 3.2(b) of the Purchase Agreement is amended and restated in its entirety as set forth below:
(b) Buyers shall:
(i) pay to Sellers Representative, for further distribution to Sellers, by wire transfer of immediately available funds to a bank account or accounts designated by Sellers Representative in the Pre-Closing Statement, an amount equal to the Estimated Purchase Price less the Escrow Amount less the Closing Brazilian Withholding Tax Amount less the Closing Transaction Expenses less Closing Indebtedness to be repaid at Closing;
(ii) retain the Closing Brazilian Withholding Tax Amount for payment to the Brazilian Tax Authorities following the Closing in accordance with Section 11.8(i);
(iii) pay, or cause to be paid, on behalf of the applicable Company or Seller, the Closing Transaction Expenses by wire transfer of immediately available funds as set forth on the Pre-Closing Statement;
(iv) pay, or cause to be paid, on behalf of the applicable Company, all of the Closing Indebtedness to be repaid at Closing to the Persons specified on the Pre-Closing Statement; provided, however, that the Santander Agreements will not be repaid at Closing and will continue in full force and effect on and after the Closing;
(v) pay to the Escrow Agent, for deposit into the Escrow Accounts, the Converted Escrow Amount as described in Section 2.2(c);
(vi) cause Limitada to pay the IOF Tax to the Brazilian Tax Authorities;
(vii) cause Film Trading to assume the Intercompany Debt pursuant to the Debt Assumption Agreement as partial payment for the Quotas in the US Dollar equivalent of the aggregate amount of the Intercompany Debt; and
(viii) deliver, or cause to be delivered, to Sellers Representative each of the documents, certificates and items required to be delivered by Buyers pursuant to Article IX.
7
1.7 Sections 5.10(j) and 5.10(k) of the Purchase Agreement. Sections 5.10(j) and 5.10(k) of the Purchase Agreement are amended and restated in their entirety as set forth below:
(j) For United States Tax purposes, neither of the Companies will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Accounting Effective Date as a result of any: (A) change in, or use of an improper, method of accounting for a taxable period (or portion thereof) ending on or prior to the Accounting Effective Date; (B) closing agreement as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. Tax Law) executed prior to the Closing; (C) installment sale or open transaction disposition made on or prior to the Accounting Effective Date; (D) prepaid amount received or deferred revenue accrued prior to the Closing; or (E) gain recognition agreement to which any of either Company is a party under Section 367 of the Code (or any corresponding or similar provision of applicable Tax Law).
(k) Neither Company will be required to pay any amount of Tax deferred as a result of an election made pursuant to Section 965(h) of the Code and the Treasury Regulations (or other guidance) issued thereunder after the Accounting Effective Date.
1.8 5.10 of the Purchase Agreement. The final paragraph of Section 5.10 of the Purchase Agreement is amended to replace the reference to Closing Date with Accounting Effective Date.
1.9 Section 7.1(b) of the Purchase Agreement. Section 7.1(b) of the Purchase Agreement is amended and restated in its entirety as set forth below:
(b) On or prior to the Closing Date, Sellers will terminate, or will cause the termination of, all Affiliate Contracts except for the Intercompany Indebtedness that is to be assumed by Film Trading pursuant to the Debt Assumption Agreement.
1.10 Section 7.6(a) of the Purchase Agreement. Section 7.6(a) of the Purchase Agreement is amended and restated in its entirety as set forth below:
(a) For the period commencing immediately following the Closing and ending on December 31 of the year following the year in which the Closing occurs (the Continuation Period), Buyers agree to use commercially reasonable efforts to provide or cause one of their Affiliates (including the Companies) to provide to individuals employed by each Company immediately prior to the Closing who continue employment with either Buyer or any of its Affiliates after the Closing (the Continuing Employees) (i) compensation (including salary or hourly wage and incentive bonus opportunity) that is not less than such employees compensation in effect immediately before the Closing, and (ii) benefits (including severance arrangements, where applicable) that are, in the aggregate, comparable to the benefits provided to such employees immediately before the Closing, except that any equity-based compensation arrangements and any sale, retention or change in control payments shall not be taken into account for purposes of determining comparability. For the avoidance of doubt, all Continuing Employees of Limitada will have the rights afforded to them under applicable Brazilian employment-related Laws.
8
1.11 Sections 8.4(h) through 8.4(n) of the Purchase Agreement. Sections 8.4(h) through 8.4(n) of the Purchase Agreement are amended and restated in their entirety as set forth below:
(h) the Escrow Agreement, dated as of approximately two Business Days prior to Closing, duly executed by Sellers Representative and the Escrow Agent;
(i) such payoff letters, termination agreements, termination statements and other releases from each holder of Closing Indebtedness to be repaid at Closing as set forth in the Pre-Closing Statement, in each case, as Buyers Representative shall have reasonably requested, to enable the Companies to repay such Indebtedness at or prior to the Closing;
(j) a certificate in form and substance as required under Section 1.1445-2(b) of the Treasury Regulations, stating that LatAm is not a foreign person subject to the proviso in the last sentence of Section 11.8(i);
(k) releases duly executed by each employee of Terphane LLC listed under subsection (A) of Schedule 5.14(a)(ix) effective once such employee receives any and all payments that are due upon Closing under the Equity Awards and Incentive Agreement and constitute Transaction Expenses in accordance with the terms and conditions of such U.S. Benefits Plans;
(l) a Transition Services Agreement, effective as of the Closing Date, by and among Sellers Parent, the Companies, and, in its capacity as guarantor of the Companies following the Closing, Buyers Parent (the TSA), duly executed by Sellers Parent;
(m) a debt assumption agreement, effective on the Closing Date (the Debt Assumption Agreement), between LatAm, as assignor, and Film Trading, as assignee, and acknowledged and agreed to by Limitada, pursuant to which LatAm assigns and transfers to Film Trading, and Film Trading accepts and assumes from LatAm, the Intercompany Debt, duly executed by LatAm and Limitada; and
(n) a Termination Agreement, effective as of the Closing Date, between LatAm and Limitada, terminating the 2019 Credit Facility, duly executed by LatAm and Limitada, except for the Intercompany Debt to be assumed by Film Trading pursuant to the Debt Assumption Agreement.
1.12 Sections 9.4(d) through 9.4(f) of the Purchase Agreement. Sections 9.4(d) through 9.4(f) of the Purchase Agreement are amended and restated in their entirety as set forth below:
(d) the Escrow Agreement, dated as of approximately two Business Days prior to the Closing Date, duly executed by Film Trading;
(e) the TSA, duly executed by the Companies and Buyers Parent; and
9
(f) the Debt Assumption Agreement, duly executed by Film Trading.
1.13 Section 10.1(d) of the Purchase Agreement. Section 10.1(d) of the Purchase Agreement is amended and restated in its entirety as set forth below:
(d) by Buyers Representative or Sellers Representative, upon written notice to the other, if the transactions contemplated hereby have not been consummated on or before December 1, 2024 (the Termination Date); except that neither Buyers Representative nor Sellers Representative shall be entitled to terminate this Agreement pursuant to this Section 10.1(d) if the willful breach of (i) a Buyer or the Buyers Representative, or (ii) a Seller or the Sellers Representative, as applicable, of this Agreement has prevented or materially delayed the consummation of the transactions contemplated hereby.
1.14 Sections 11.8(a) and 11.8(b) of the Purchase Agreement. Each reference to Closing Date in Sections 11.8(a) and 11.8(b) of the Purchase Agreement is amended and replaced with Accounting Effective Date.
1.15 Section 11.8(i) of the Purchase Agreement. Section 11.8(i) of the Purchase Agreement is amended and restated in its entirety as set forth below:
(i) Brazilian Withholding Tax Amounts. Annex 11.8(i) sets forth a description of the procedures that the Parties will apply to calculate each Brazilian Withholding Tax Amount and related Base Consideration and Net Working Capital allocations. At least two Business Days before the Closing Date, Sellers Representative shall provide Buyers with information relating to the calculation of the Closing Brazilian Withholding Tax Amount according to the procedures described in Annex 11.8(i), in reasonable detail, and with appropriate supporting documentation and calculations, including each Sellers tax basis and holding period in the Quotas owned by each of them, the amount of each Sellers gain with respect to the sale of such Quotas pursuant to this Agreement, and the Closing Brazilian Withholding Tax Amount that Sellers have calculated will be imposed in accordance with the Tax Laws of the Federative Republic of Brazil. Sellers Representative shall cooperate in a commercially reasonable manner with Buyers Representative and its Brazilian tax advisors to promptly provide additional information, answer questions and consult regarding the calculation of the Closing Brazilian Withholding Tax Amount. Sellers Representative and Buyers Representative shall use commercially reasonable good faith efforts to agree on the amount of the Closing Brazilian Withholding Tax Amount. If Sellers Representative and Buyers Representative have not entered into such agreement at least one Business Day before the Closing Date, then Film Trading shall withhold from the consideration payable to Sellers under this Agreement on the Closing Date and pay over to the Brazilian Tax Authority no later than the last Business Day of month immediately following the month during which the Closing Date occurs that amount of Tax based on the information provided by Sellers Representative relating to the calculation of the Brazilian Withholding Tax Amount, and, so long as Film Trading pays the full amount of the Closing Brazilian Withholding Tax
10
Amount timely in accordance with this sentence, Sellers shall in any case be fully responsible and liable for the effects of any assessment by the Brazilian Tax Authority that the deduction and withholding amounts were less than the amounts actually due under the applicable Law. Buyers Representative undertakes to provide to Sellers Representative, within 15 Business Days after payment of the Closing Brazilian Withholding Tax Amount, evidence of payment of the Closing Brazilian Withholding Tax Amount, indicating the amount of Closing Brazilian Withholding Tax Amount, including any copies of receipts received or obtainable from a Brazilian Tax Authority. For the avoidance of doubt, any amount withheld by Film Trading pursuant to this Section 11.8(i) and paid to the Brazilian Tax Authorities shall be considered to have been paid by Film Trading to Sellers. If any additional Brazilian Withholding Tax Amount becomes payable or refundable after the Closing Date, as applicable, the Parties will follow the same procedures and timelines set forth in this Section 11.8(i) and Annex 11.8(i) attached hereto in calculating and paying over to, or recouping from, the Brazilian Tax Authorities such Brazilian Withholding Tax Amounts.
1.16 Buyers Parents Guaranty. Subsection (i) of the defined term Buyers Guaranteed Obligations is amended and restated in its entirety as follows:
(i) Buyers payment of the amounts set forth in Sections 3.2(b)(i) through 3.2(b)(vi).
1.17 Permitted Liens. Annex I to the Purchase Agreement (Permitted Liens) is amended as shown on Exhibit A hereto.
1.18 Identified Tax and Labor Matters Analysis. Annex 8.8 to the Purchase Agreement (Identified Tax and Labor Matters Analysis) is updated in the form attached as Exhibit B hereto as contemplated by Section 11.5 of the Purchase Agreement.
1.19 Terms of the Purchase Agreement. Except as expressly amended or modified by this Amendment, the terms of the Purchase Agreement remain in full force and effect as the binding obligation of each party hereto. Each party hereto ratifies, reaffirms and confirms its respective rights, benefits, duties, obligations and liabilities as contemplated by the Purchase Agreement.
[Signature Page Follows]
11
IN WITNESS WHEREOF, Buyers and Buyers Parent have executed and delivered this Amendment as of the date first above written.
BUYERS AND BUYERS PARENT: | ||
OBEN US, LLC | ||
By: | /s/ Jamil Zaidan Saba | |
Name: | Jamil Zaidan Saba | |
Title: | Director | |
FILM TRADING IMPORTAÇÃO E REPRESENTAÇÃO LTDA. | ||
By: | /s/ Nikolas Zaidan Abusada | |
Name: | Nikolas Zaidan Abusada | |
Title: | Legal Representative | |
OBEN HOLDING GROUP S.A.C. | ||
By: | /s/ Jamil Zaidan Saba | |
Name: | Jamil Zaidan Saba | |
Title: | Legal Proxy |
[Buyers and Buyers Parents Signature Page to Amendment
to Purchase and Sale Agreement]
IN WITNESS WHEREOF, Sellers, Sellers Parent and the Companies have executed and delivered this Agreement as of the date first above written.
SELLERS AND SELLERS PARENT: | COMPANIES: | |||||||
TREDEGAR FILM PRODUCTS (LATIN AMERICA), INC. | TERPHANE LLC | |||||||
By: | /s/ D. Andrew Edwards |
By: | /s/ D. Andrew Edwards | |||||
Name: | D. Andrew Edwards | Name: |
D. Andrew Edwards | |||||
Title: | President | Title: |
Vice President | |||||
TERPHANE ACQUISITION CORP. II | TERPHANE LIMITADA | |||||||
By: TERPHANE HOLDINGS LLC, | ||||||||
its sole Director | ||||||||
By: | /s/ D. Andrew Edwards |
By: | /s/ José Bosco Silveira | |||||
Name: | D. Andrew Edwards | Name: |
José Bosco Silveira | |||||
Title: | Vice President | Title: |
Managing Director | |||||
TAC HOLDINGS, LLC | ||||||||
By: | /s/ D. Andrew Edwards |
|||||||
Name: | D. Andrew Edwards | |||||||
Title: | Vice President | |||||||
TREDEGAR INVESTMENTS LLC | ||||||||
By: | /s/ D. Andrew Edwards |
|||||||
Name: |
D. Andrew Edwards |
|||||||
Title: |
President |
|||||||
TREDEGAR CORPORATION | ||||||||
By: | /s/ D. Andrew Edwards |
|||||||
Name: |
D. Andrew Edwards |
|||||||
Title: | Vice President and CFO |
[Sellers, Sellers Parents and the Companies Signature Page to Amendment
to Purchase and Sale Agreement]
Exhibit 99.1
Tredegar Corporation | Contact: | |
Corporate Communications | Neill Bellamy | |
1100 Boulders Parkway | Phone: 804/330-1211 | |
Richmond, Virginia 23225 | E-mail: neill.bellamy@tredegar.com | |
Website: www.tredegar.com |
FOR IMMEDIATE RELEASE
Tredegar Completes Sale of Terphane to Oben Group
RICHMOND, VA, November 1, 2024 Tredegar Corporation (NYSE:TG) (Tredegar) announced today that it has completed the previously announced sale of Terphane, its flexible packaging films business headquartered in Brazil, to Oben Group (Oben).
Commenting on the sale, John Steitz, Tredegars president and chief executive officer said, The sale of Terphane completes a strategic goal that weve been working on for well over a year. We believe that Terphane will have greater scale and growth opportunities with Oben, a global player in the highly competitive flexible films industry. We wish the best for the employees and stakeholders of Terphane and Oben.
Gonzalo Belaunde, Obens chief executive officer, said, We are pleased to complete the acquisition of Terphane. We believe that combining our capabilities will improve the service and quality provided to our customers and markets. We welcome Terphane to the Oben team.
On September 1, 2023, Tredegar entered into an agreement to sell Terphane to Oben for net cash-free and debt-free base consideration of $116 million. Tredegar expects to realize after-tax net cash-free and debt-free cash proceeds of $85 million (after deducting projected Brazil withholding taxes, net working capital adjustments, escrow funds, US capital gains taxes and transaction expenses), including $78 million at closing and $7 million from the release of certain escrow funds within 120 days of closing (the Post-Closing Review Period). Expected amounts are based on Terphanes estimated balance sheet on the closing date, which may change during the Post-Closing Review Period as accounts for the applicable period are finalized.
Tredegar is an industrial manufacturer with two primary businesses: custom aluminum extrusions for the North American building & construction, automotive and specialty end-use markets and surface protection films for high technology applications in the global electronics industry. With approximately 1,500 employees, Tredegar operates manufacturing facilities in North America and Asia.
Oben is an important player in the market of inputs for the flexible packaging industry with more than 32 years of experience in the production of state-of-the-art flexible films having strategic locations in more than 17 countries with sales to more than 40 countries in the Americas, Europe and Africa. It has a diversified portfolio that includes BOPP, BOPET, BOPE, BOPA, CPP, Extrusion Coated as well as Thermoformed Products.
Tredegar Completes Sale of Terphane to Oben Group, page 2 |
Forward-Looking Statements
Some of the information contained in this press release may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. When we use the words believe, estimate, anticipate, appear to, expect, project, plan, likely, may and similar expressions, Tredegar does so to identify forward-looking statements. Such statements are based on Tredegars then-current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements. It is possible that actual results may differ, possibly materially, from the forward-looking statements provided in this press release. Accordingly, you should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ from expectations include, without limitation, the factors discussed in the reports Tredegar files with or furnishes to the Securities and Exchange Commission (the SEC) from time to time, including the risks and important factors set forth in additional detail in Risk Factors in Part I, Item 1A of Tredegars Annual Report on Form 10-K for the year ended December 31, 2023. Readers are urged to review and consider carefully the disclosures Tredegar makes in its filings with the SEC.
Tredegar does not undertake, and expressly disclaims any duty, to update any forward-looking statement made in this press release to reflect any change in managements expectations or any change in conditions, assumptions or circumstances on which such statements are based, except as required by applicable law.
CONTACT:
Neill Bellamy, 804-330-1211
neill.bellamy@tredegar.com
###
Exhibit 99.2
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
On November 1, 2024, pursuant to the previously announced Purchase and Sale Agreement, dated September 1, 2023 (the Purchase Agreement), by and among Terphane LLC (Terphane LLC), Terphane Limitada (Limitada and together with Terphane LLC, the Companies or Terphane), Tredegar Film Products (Latin America), Inc. (LatAm), Terphane Acquisition Corp. II (Tac II), TAC Holdings, LLC (TAC), Tredegar Investments LLC (Investments and together with LatAm, Tac II and TAC, the Sellers), and Tredegar Corporation (Tredegar), in its capacity as representative of the Sellers and for the purposes of guaranteeing Sellers payment and performance obligations under the Purchase Agreement, Packfilm US, LLC (Packfilm), Film Trading Importaçãcao e Representaçãcao Ltda. (Film Trading and together with Packfilm, the Buyers) and Oben Holding Group S.A.C. (Oben), in its capacity as representative of the Buyers and for the purposes of guaranteeing Buyers payment and performance obligations under the Purchase Agreement, the Sellers completed the sale to the Buyers of 100% of the issued and outstanding equity interests of the Companies (the Terphane Divestiture).
On November 1, 2024 (Closing Date), Tredegar completed the sale of Terphane to Oben. At closing, Tredegar received $60 million in cash, which is net of Terphane debt assumed by Oben of $20 million and Terphane cash retained by Oben of $2 million. Accordingly, on a cash-free and debt-free basis, the enterprise value of the Terphane Divestiture transaction at closing for Tredegar was $78 million. Tredegar anticipates receiving an additional $7 million in cash following the release of certain escrow funds within 120 days of closing. The cash proceeds received by Tredegar at closing are after deducting projected Brazil withholding taxes, net working capital adjustments, escrow funds, U.S. capital gains taxes and transaction expenses. The total estimated proceeds from the Terphane Divestiture are required to be used to pay down the outstanding borrowings under Tredegars senior secured asset-based revolving credit facility (the ABL Facility).
The following unaudited pro forma condensed consolidated financial information has been derived from Tredegars historical consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles (GAAP). The unaudited pro forma condensed consolidated balance sheet as of June 30, 2024, reflects Tredegars financial position as if the Terphane Divestiture had occurred on that date. The unaudited pro forma condensed consolidated statements of operations for the six months ended June 30, 2024, and for each of the years ended December 31, 2023, 2022, and 2021 reflect Tredegars operating results as if the Terphane Divestiture had occurred as of January 1, 2021. In addition, the unaudited pro forma condensed consolidated balance sheet and condensed consolidated statements of operations reflect certain adjustments, as described herein, that are incremental to those related to the Terphane Divestiture, as if they occurred on June 30, 2024 and January 1, 2021, respectively.
The Companies sold in the Terphane Divestiture comprise Tredegars Flexible Packaging Films business, which is currently reported by Tredegar as a separate reportable business segment. In Tredegars future public filings, the historical financial results of the Flexible Packaging Films business will be reflected in Tredegars consolidated financial statements as discontinued operations under GAAP for all periods.
The unaudited pro forma condensed consolidated financial statements and the accompanying notes should be read in conjunction with:
| Tredegars audited consolidated financial statements and accompanying notes and Managements Discussion and Analysis of Financial Condition and Results of Operations included in its Annual Report on Form 10-K for the year ended December 31, 2023; and |
| Tredegars unaudited consolidated financial statements and accompanying notes and Managements Discussion and Analysis of Financial Condition and Results of Operations included in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024. |
The unaudited pro forma condensed consolidated financial information was prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma condensed consolidated financial information was prepared for illustrative and informational purposes only and does not necessarily reflect what Tredegars results of operations or financial position would have been had the Terphane Divestiture occurred on the dates indicated. The unaudited pro forma condensed consolidated financial information has been prepared based upon the best information available to Tredegars management and is subject to the assumptions, estimates and related adjustments described below and in the accompanying notes to the unaudited pro forma condensed consolidated financial information. In addition, the unaudited pro forma condensed consolidated financial information is not necessarily indicative of Tredegars future operating results or financial position at any future date. Tredegars actual financial position and results of operations may materially differ from the pro forma amounts reflected herein due to a variety of factors. The Terphane Divestiture column removes the assets, liabilities and results of operations and also gives effect to adjustments to reflect the net cash proceeds from Oben. Management believes these assumptions and adjustments are reasonable, given the information available at the filing date.
Tredegar Corporate and Subsidiaries
Pro Forma Condensed Consolidated Balance Sheet
(Unaudited)
June 30, 2024 | ||||||||||||||||||||||||||
(in thousands) |
Historical Tredegar |
Less: Terphane Divestiture Note 1 |
Note | Use of Proceeds |
Note | Other Transaction Adjustments |
Note | Pro Forma Tredegar |
||||||||||||||||||
Assets |
||||||||||||||||||||||||||
Current assets: |
||||||||||||||||||||||||||
Cash and cash equivalents |
$ | 3,510 | $ | 56,694 | [2](i) | $ | (59,565 | ) | [3] | $ | 4,789 | [5] | $ | 5,428 | ||||||||||||
Restricted cash |
5,159 | (370 | ) | | (4,789 | ) | [5] | | ||||||||||||||||||
Accounts and other receivables, net |
83,895 | (14,159 | ) | | | 69,736 | ||||||||||||||||||||
Income taxes recoverable |
789 | | [2](iv) | | | 789 | ||||||||||||||||||||
Inventories |
89,242 | (32,895 | ) | | | 56,347 | ||||||||||||||||||||
Prepaid expenses and other |
8,170 | (1,124 | ) | | | 7,046 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total current assets |
190,765 | 8,146 | (59,565 | ) | | 139,346 | ||||||||||||||||||||
Property, plant and equipment, at cost |
538,181 | (41,594 | ) | | | 496,587 | ||||||||||||||||||||
Less: accumulated depreciation |
(366,336 | ) | 12,809 | | | (353,527 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Net property, plant and equipment |
171,845 | (28,785 | ) | | | 143,060 | ||||||||||||||||||||
Right-of-use leased assets |
16,209 | (557 | ) | | | 15,652 | ||||||||||||||||||||
Identifiable intangible assets, net |
8,811 | (606 | ) | | | 8,205 | ||||||||||||||||||||
Goodwill |
35,717 | | | | 35,717 | |||||||||||||||||||||
Deferred income taxes |
23,600 | (2,369 | ) | [2](iii) | | 7,017 | [2](iii) | 28,248 | ||||||||||||||||||
Other assets |
3,465 | (155 | ) | | | 3,310 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total assets |
$ | 450,412 | $ | (24,326 | ) | $ | (59,565 | ) | $ | 7,017 | $ | 373,538 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Liabilities and Shareholders Equity |
||||||||||||||||||||||||||
Current liabilities: |
||||||||||||||||||||||||||
Accounts payable |
$ | 93,006 | $ | (24,254 | ) | $ | | $ | | $ | 68,752 | |||||||||||||||
Accrued expenses |
27,015 | (6,925 | ) | | | 20,090 | ||||||||||||||||||||
Lease liability, short-term |
2,877 | (164 | ) | | | 2,713 | ||||||||||||||||||||
ABL revolving facility (matures on June 30, 2026) |
122,000 | | (59,565 | ) | [3] | (62,435 | ) | [5] | | |||||||||||||||||
Income taxes payable |
257 | (205 | ) | [2](iv) | | | 52 | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total current liabilities |
245,155 | (31,548 | ) | (59,565 | ) | (62,435 | ) | 91,607 | ||||||||||||||||||
Lease liability, long-term |
14,610 | (399 | ) | | | 14,211 | ||||||||||||||||||||
Long-term debt |
20,000 | (20,000 | ) | | 62,435 | [5] | 62,435 | |||||||||||||||||||
Pension and other postretirement benefit obligations, net |
6,524 | | | | 6,524 | |||||||||||||||||||||
Other non-current liabilities |
4,159 | (182 | ) | | | 3,977 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total liabilities |
290,448 | (52,129 | ) | (59,565 | ) | | 178,754 | |||||||||||||||||||
Shareholders equity: |
||||||||||||||||||||||||||
Common stock, no par value |
62,493 | | | | 62,493 | |||||||||||||||||||||
Common stock held in trust for savings restoration plan |
(2,233 | ) | | | | (2,233 | ) | |||||||||||||||||||
Accumulated other comprehensive income (loss): |
||||||||||||||||||||||||||
Foreign currency translation adjustment |
(90,273 | ) | 100,379 | [2](ii) | | | 10,106 | |||||||||||||||||||
Gain (loss) on derivative financial instruments |
(564 | ) | (60 | ) | [2](ii) | | | (624 | ) | |||||||||||||||||
Pension and other postretirement benefit adjustments |
484 | | | | 484 | |||||||||||||||||||||
Retained earnings |
190,057 | (72,516 | ) | [2](ii) | 7,017 | [2](iii) | 124,558 | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Shareholders equity |
159,964 | 27,803 | | 7,017 | 194,784 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total liabilities and shareholders equity |
$ | 450,412 | $ | (24,326 | ) | $ | (59,565 | ) | $ | 7,017 | $ | 373,538 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
See the accompanying Notes to Pro Forma Condensed Consolidated Financial Statements
Tredegar Corporate and Subsidiaries
Pro Forma Condensed Consolidated Statement of Operations
(Unaudited)
Six Months Ended June 30, 2024 | ||||||||||||||||||||||||
(in thousands, except per share data) |
Historical Tredegar |
Less: Terphane Divestiture Note 1 |
Note | Use of Proceeds |
Note | Pro Forma Tredegar |
||||||||||||||||||
Revenues and other items: |
||||||||||||||||||||||||
Sales |
$ | 365,971 | $ | (68,059 | ) | $ | | $ | 297,912 | |||||||||||||||
Other income (expense), net |
331 | (3 | ) | | 328 | |||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
366,302 | (68,062 | ) | | 298,240 | ||||||||||||||||||||
Costs and expenses: |
||||||||||||||||||||||||
Cost of goods sold |
290,708 | (56,589 | ) | | 234,119 | |||||||||||||||||||
Freight |
13,748 | (3,403 | ) | | 10,345 | |||||||||||||||||||
Selling, general and administrative |
38,144 | (2,529 | ) | [6 | ] | | 35,615 | |||||||||||||||||
Research and development |
519 | (396 | ) | | 123 | |||||||||||||||||||
Amortization of identifiable intangibles |
948 | (48 | ) | | 900 | |||||||||||||||||||
Pension and postretirement benefits |
109 | | | 109 | ||||||||||||||||||||
Interest expense |
6,834 | (1,142 | ) | (2,489 | ) | [3 | ] | 3,203 | ||||||||||||||||
Asset impairments and costs associated with exit and disposal activities, net of adjustments |
587 | | | 587 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Total |
351,597 | (64,107 | ) | (2,489 | ) | 285,001 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Income (loss) before income taxes |
14,705 | (3,955 | ) | 2,489 | 13,239 | |||||||||||||||||||
Income tax expense (benefit) |
2,625 | (752 | ) | 473 | [4 | ] | 2,346 | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Net income (loss) |
$ | 12,080 | $ | (3,203 | ) | $ | 2,016 | $ | 10,893 | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
$ | 0.35 | $ | 0.32 | ||||||||||||||||||||
Diluted |
$ | 0.35 | $ | 0.32 | ||||||||||||||||||||
Shares used to compute earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
34,350 | 34,350 | ||||||||||||||||||||||
Diluted |
34,350 | 34,350 |
See the accompanying Notes to Pro Forma Condensed Consolidated Financial Statements
Tredegar Corporate and Subsidiaries
Pro Forma Condensed Consolidated Statement of Operations
(Unaudited)
Year Ended December 31, 2023 | ||||||||||||||||||||||||
(in thousands, except per share data) |
Historical Tredegar |
Less: Terphane Divestiture Note 1 |
Note | Use of Proceeds |
Note | Pro Forma Tredegar |
||||||||||||||||||
Revenues and other items: |
||||||||||||||||||||||||
Sales |
$ | 704,825 | $ | (131,502 | ) | $ | | $ | 573,323 | |||||||||||||||
Other income (expense), net |
(2,147 | ) | (2 | ) | | (2,149 | ) | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
702,678 | (131,504 | ) | | 571,174 | ||||||||||||||||||||
Costs and expenses: |
||||||||||||||||||||||||
Cost of goods sold |
599,110 | (118,669 | ) | | 480,441 | |||||||||||||||||||
Freight |
26,933 | (5,177 | ) | | 21,756 | |||||||||||||||||||
Selling, general and administrative |
76,207 | (10,819 | ) | [6 | ] | | 65,388 | |||||||||||||||||
Research and development |
3,761 | (867 | ) | | 2,894 | |||||||||||||||||||
Amortization of identifiable intangibles |
1,897 | (139 | ) | | 1,758 | |||||||||||||||||||
Pension and postretirement benefits |
10,844 | | | 10,844 | ||||||||||||||||||||
Interest expense |
11,607 | (384 | ) | (4,907 | ) | [3 | ] | 6,316 | ||||||||||||||||
Asset impairments and costs associated with exit and disposal activities, net of adjustments |
5,167 | (107 | ) | | 5,060 | |||||||||||||||||||
Pension settlement loss |
92,291 | | | 92,291 | ||||||||||||||||||||
Goodwill impairment |
34,891 | | | 34,891 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Total |
862,708 | (136,162 | ) | (4,907 | ) | 721,639 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Income (loss) before income taxes |
(160,030 | ) | 4,658 | 4,907 | (150,465 | ) | ||||||||||||||||||
Income tax expense (benefit) |
(54,125 | ) | 1,375 | 1,450 | [4 | ] | (51,300 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Net income (loss) |
$ | (105,905 | ) | $ | 3,283 | $ | 3,457 | $ | (99,165 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
$ | (3.10 | ) | $ | (2.91 | ) | ||||||||||||||||||
Diluted |
$ | (3.10 | ) | $ | (2.91 | ) | ||||||||||||||||||
Shares used to compute earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
34,133 | 34,133 | ||||||||||||||||||||||
Diluted |
34,133 | 34,133 |
See the accompanying Notes to Pro Forma Condensed Consolidated Financial Statements
Tredegar Corporate and Subsidiaries
Pro Forma Condensed Consolidated Statement of Operations
(Unaudited)
Year Ended December 31, 2022 | ||||||||||||||||||||||||
(in thousands, except per share data) |
Historical Tredegar |
Less: Terphane Divestiture Note 1 |
Note | Use of Proceeds |
Note | Pro Forma Tredegar |
||||||||||||||||||
Revenues and other items: |
||||||||||||||||||||||||
Sales |
$ | 938,564 | $ | (176,579 | ) | $ | | $ | 761,985 | |||||||||||||||
Other income (expense), net |
1,009 | 51 | | 1,060 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
939,573 | (176,528 | ) | | 763,045 | ||||||||||||||||||||
Costs and expenses: |
||||||||||||||||||||||||
Cost of goods sold |
764,042 | (133,493 | ) | | 630,549 | |||||||||||||||||||
Freight |
34,982 | (8,440 | ) | | 26,542 | |||||||||||||||||||
Selling, general and administrative |
78,790 | (9,179 | ) | [6 | ] | | 69,611 | |||||||||||||||||
Research and development |
6,214 | (891 | ) | | 5,323 | |||||||||||||||||||
Amortization of identifiable intangibles |
2,520 | (396 | ) | | 2,124 | |||||||||||||||||||
Pension and postretirement benefits |
14,569 | | | 14,569 | ||||||||||||||||||||
Interest expense |
4,990 | 78 | (927 | ) | [3 | ] | 4,141 | |||||||||||||||||
Asset impairments and costs associated with exit and disposal activities, net of adjustments |
622 | | | 622 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Total |
906,729 | (152,321 | ) | (927 | ) | 753,481 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Income (loss) before income taxes |
32,844 | (24,207 | ) | 927 | 9,564 | |||||||||||||||||||
Income tax expense (benefit) |
4,389 | (7,705 | ) | 295 | [4 | ] | (3,021 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Net income (loss) |
$ | 28,455 | $ | (16,502 | ) | $ | 632 | $ | 12,585 | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
$ | 0.84 | $ | 0.37 | ||||||||||||||||||||
Diluted |
$ | 0.84 | $ | 0.37 | ||||||||||||||||||||
Shares used to compute earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
33,806 | 33,806 | ||||||||||||||||||||||
Diluted |
33,826 | 33,826 |
See the accompanying Notes to Pro Forma Condensed Consolidated Financial Statements
Tredegar Corporate and Subsidiaries
Pro Forma Condensed Consolidated Statement of Operations
(Unaudited)
Year Ended December 31, 2021 | ||||||||||||||||||||||||
(in thousands, except per share data) |
Historical Tredegar |
Less: Terphane Divestiture Note 1 |
Note | Use of Proceeds |
Note | Pro Forma Tredegar |
||||||||||||||||||
Revenues and other items: |
||||||||||||||||||||||||
Sales |
$ | 826,455 | $ | (147,311 | ) | $ | | $ | 679,144 | |||||||||||||||
Other income (expense), net |
20,265 | (8,469 | ) | | 11,796 | |||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
846,720 | (155,780 | ) | | 690,940 | ||||||||||||||||||||
Costs and expenses: |
||||||||||||||||||||||||
Cost of goods sold |
649,690 | (102,678 | ) | | 547,012 | |||||||||||||||||||
Freight |
28,232 | (7,334 | ) | | 20,898 | |||||||||||||||||||
Selling, general and administrative |
74,964 | (7,231 | ) | [6 | ] | | 67,733 | |||||||||||||||||
Research and development |
6,347 | (635 | ) | | 5,712 | |||||||||||||||||||
Amortization of identifiable intangibles |
1,704 | (392 | ) | | 1,312 | |||||||||||||||||||
Pension and postretirement benefits |
14,160 | | | 14,160 | ||||||||||||||||||||
Interest expense |
3,386 | 46 | (395 | ) | [3 | ] | 3,037 | |||||||||||||||||
Asset impairments and costs associated with exit and disposal activities, net of adjustments |
1,127 | | | 1,127 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Total |
779,610 | (118,224 | ) | (395 | ) | 660,991 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Income (loss) before income taxes |
67,110 | (37,556 | ) | 395 | 29,949 | |||||||||||||||||||
Income tax expense (benefit) |
9,284 | (8,306 | ) | 87 | [4 | ] | 1,065 | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Net income (loss) |
$ | 57,826 | $ | (29,250 | ) | $ | 308 | $ | 28,884 | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
$ | 1.72 | $ | 0.86 | ||||||||||||||||||||
Diluted |
$ | 1.72 | $ | 0.86 | ||||||||||||||||||||
Shares used to compute earnings (loss) per share: |
||||||||||||||||||||||||
Basic |
33,563 | 33,563 | ||||||||||||||||||||||
Diluted |
33,670 | 33,670 |
See the accompanying Notes to Pro Forma Condensed Consolidated Financial Statements
Notes to Unaudited Pro Forma Condensed Consolidated Financial Information
Terphane Business Discontinued Operations
Note 1.
The Terphane Divestiture reflects Tredegars assets, liabilities, shareholders equity, revenue and expenses of the Flexible Packaging Films business prepared in accordance with discontinued operations guidance set forth in Accounting Standards Codification (ASC) 205. Furthermore, an allocated portion of the historical income tax expense (benefit) has been attributed to the Terphane Divestiture discontinued operations pursuant to ASC 740 Income Taxes for each of the periods.
The amounts are considered preliminary, and as such, actual results could materially differ from these estimates.
Use of Proceeds and Other Transaction Adjustments
Note 2.
Reflects the Terphane Divestiture pursuant to the Purchase and Sale Agreement, adjustments required to record the estimated cash proceeds (net of transaction costs) received in connection with the Terphane Divestiture and recognition of the estimated loss on sale in retained earnings as if the transaction had occurred on June 30, 2024.
(i) | Estimated net cash proceeds in connection with the Terphane Divestiture are as follows: |
(in thousands) |
||||
Base purchase price |
$ | 116,000 | ||
Purchase price adjustment(a) |
(41,553 | ) | ||
Costs to sell(b) |
(4,114 | ) | ||
Brazil withholding taxes(c) |
(10,768 | ) | ||
|
|
|||
Net cash proceeds(d) |
$ | 59,565 | ||
Terphane cash and cash equivalents as of June 30, 2024 |
(2,871 | ) | ||
|
|
|||
Cash and cash equivalents as shown on the unaudited pro forma condensed consolidated balance sheet |
$ | 56,694 | ||
|
|
a. | Purchase price adjustment includes items specified in the terms of the Purchase and Sale Agreement, including preliminary estimates for closing net working capital, closing indebtedness, retention incentives, and escrow funds. |
b. | Represents the estimated impact of the costs associated with the Terphane Divestiture, such as legal, consulting, accounting fees and other professional services incurred to effect the Terphane Divestiture that are not already reflected in historical Tredegar or Terphane results. |
c. | Represents Brazilian withholding tax paid to the Brazilian Tax Authorities on the Closing Date, which is a foreign tax credit for Tredegar that will reduce U.S. taxes to be paid over the next ten years. |
d. | At closing, Tredegar received $60 million in cash, which is net of Terphane debt assumed by Oben of $20 million and Terphane cash retained by Oben of $2 million. Accordingly, on a cash-free and debt-free basis, the enterprise value of the Terphane Divestiture transaction at closing for Tredegar was $78 million. Tredegar anticipates receiving an additional $7 million in cash following the release of certain escrow funds within 120 days of closing. The total estimated proceeds from the Terphane Divestiture are required to be used to pay down the outstanding ABL Facility debt. |
(ii) | Estimated loss on the Terphane Divestiture, assuming Tredegar had completed the transaction as of June 30, 2024, is as follows: |
(in thousands) |
||||
Net cash proceeds |
$ | 59,565 | ||
Net assets sold |
(31,762 | ) | ||
Realized accumulated other comprehensive loss: |
||||
Foreign currency translation adjustment |
(100,379 | ) | ||
Gain on derivative financial instruments |
60 | |||
|
|
|||
Pre-tax loss on sale |
$ | (72,516 | ) | |
Estimated accrued tax expense (benefit) |
(7,017 | ) | ||
|
|
|||
Estimated after-tax loss on sale |
$ | (65,499 | ) | |
|
|
For purposes of the unaudited pro forma condensed consolidated balance sheet, the estimated loss recognized in retained earnings is based on the net carrying value of Terphane as of June 30, 2024 rather than as of the Closing Date. As a result, the estimated loss reflected herein may differ materially from the actual loss on the Terphane Divestiture as of the Closing Date because of the differences in the carrying value of assets and liabilities at the Closing Date.
(iii) | Includes an adjustment of $4.6 million for changes in deferred taxes as a result of the Terphane Divestiture. |
(iv) | Includes an adjustment of $0.2 million for tax receivables and tax liabilities as a result of the Terphane Divestiture. |
Note 3.
This adjustment reflects the estimated impact on the unaudited pro forma condensed consolidated balance sheet as of June 30, 2024, of the $59.6 million net cash proceeds from the Terphane Divestiture required to be used to pay down the outstanding borrowings under the ABL Facility. As a result of the required repayment towards the outstanding ABL Facility debt, an adjustment has been made to the Tredegar historical ABL Facility interest expense. The additional $7 million expected to be released from escrow funds within 120 days of closing will also used to pay down the ABL Facility once received.
Note 4.
This adjustment reflects the income tax effects on an accrual basis of the adjustments describe herein using enacted statutory rates applicable in each period in which pre-tax adjustments were made.
Note 5.
On November 1, 2024, with the closing of the Terphane Divestiture, the ABL Adjustment Date (as defined in the ABL Facility as the earlier of September 30, 2025 or the date the Company receives the proceeds from Terphane Divestiture) has occurred.
Under the terms of the ABL Facility, certain domestic bank accounts are subject to blocked account agreements, each of which contains a springing feature whereby the lenders may exercise control over those accounts during a cash dominion period (any such period, a Cash Dominion Period). A Cash Dominion Period was implemented on the date the Company entered into the ABL Facility and remained in effect at all times prior to the ABL Adjustment Date. Prior to the ABL Adjustment Date, cash receipts that have not yet been applied to the ABL Facility were classified as restricted cash. Accordingly, this pro forma adjustment represents a reclassification to cash and cash equivalents as the unapplied cash receipts are no longer restricted after the ABL Adjustment Date.
Moreover, the ABL Facility has customary representations and warranties, including, as a condition to each borrowing, that all such representations and warranties are true and correct in all material respects (including a representation that no Material Adverse Effect (as defined in the ABL Facility) has occurred since December 31, 2022). In the event that Tredegar cannot certify that all conditions to the borrowing have been met, the lenders can restrict Tredegars future borrowings under the ABL Facility. As the Cash Dominion Period is no longer in effect, the outstanding debt under the ABL Facility (all contractual payments due on June 30, 2026) has been reclassified to long-term debt in the unaudited pro forma condensed consolidated balance sheet.
Note 6.
For the periods ended June 30, 2024, December 31, 2023, and December 31, 2022, the Company incurred non-routine legal, consulting, accounting fees and other professional services related to the Terphane Divestiture of $0.7 million, $5.0 million, and $0.5 million, respectively. These amounts are included in the Terphane Divestiture discontinued operations. There were no non-routine expenses incurred for the period ended December 31, 2021.